Journal
CLINICAL RESEARCH IN CARDIOLOGY
Volume 109, Issue 10, Pages 1197-1222Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00392-020-01636-7
Keywords
Cardio-oncology; Cardiotoxicity; Survivorship programs; Cancer therapy; Chemotherapy
Categories
Funding
- Projekt DEAL
Ask authors/readers for more resources
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available